ACE and hydrops fetalis: The 2014 Prospective Comparison of Angiotensin Receptor/Neprilysin Inhibitor (ARNI) with Angiotensin II Type 1 Receptor Blocker (ACEI) to Determine Impact on Global Mortality and Morbidity in HF (PARADIGM-HF) trial found that ARNI and valsartan were more effective than ACE inhibitor enalapril in reducing morbidity and mortality in patients with chronic HFrEF [7].